Search Results - "Munemoto, Y."

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial by Yamazaki, K., Yamanaka, T., Shiozawa, M., Manaka, D., Kotaka, M., Gamoh, M., Shiomi, A., Makiyama, A., Munemoto, Y., Rikiyama, T., Fukunaga, M., Ueki, T., Shitara, K., Shinkai, H., Tanida, N., Oki, E., Sunami, E., Ohtsu, A., Maehara, Y., Yoshino, T.

“…Oxaliplatin-based adjuvant chemotherapy may be associated with debilitating peripheral sensory neuropathy (PSN) in patients with high-risk stage II colon…”
Get full text

Modified Gant–Miwa–Thiersch procedure (mucosal plication with anal encircling) for rectal prolapse by Iida, Y., Honda, K., Saitou, H., Munemoto, Y., Tanaka, H.

“…Aim Rectal prolapse (RP) is usually associated with elderly women and is well recognized as having a detrimental effect on quality of life. A number of…”
Get full text

SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer by Munemoto, Y., Nakamura, M., Takahashi, M., Kotaka, M., Kuroda, H., Kato, T., Minagawa, N., Noura, S., Fukunaga, M., Kuramochi, H., Touyama, T., Takahashi, T., Miwa, K., Satake, H., Kurosawa, S., Miura, T., Mishima, H., Sakamoto, J., Oba, K., Nagata, N.

“…Fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (FOLFOX) plus panitumumab therapy is a commonly used first-line chemotherapy for metastatic colorectal…”
Get full text

A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC) by Oki, E., Murata, A., Yoshida, K., Maeda, K., Ikejiri, K., Munemoto, Y., Sasaki, K., Matsuda, C., Kotake, M., Suenaga, T., Matsuda, H., Emi, Y., Kakeji, Y., Baba, H., Hamada, C., Saji, S., Maehara, Y.

“…Preventing distant recurrence and achieving local control are important challenges in rectal cancer treatment, and use of adjuvant chemotherapy has been…”
Get full text

Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy by Kanai, M., Kawaguchi, T., Kotaka, M., Manaka, D., Hasegawa, J., Takagane, A., Munemoto, Y., Kato, T., Eto, T., Touyama, T., Matsui, T., Shinozaki, K., Matsumoto, S., Mizushima, T., Mori, M., Sakamoto, J., Ohtsu, A., Yoshino, T., Saji, S., Matsuda, F.

“…The severity of oxaliplatin (L-OHP)-induced peripheral sensory neuropathy (PSN) exhibits substantial interpatient variability, and some patients suffer from…”
Get full text

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study by Iwamoto, S., Takahashi, T., Tamagawa, H., Nakamura, M., Munemoto, Y., Kato, T., Hata, T., Denda, T., Morita, Y., Inukai, M., Kunieda, K., Nagata, N., Kurachi, K., Ina, K., Ooshiro, M., Shimoyama, T., Baba, H., Oba, K., Sakamoto, J., Mishima, H.

“…A targeted agent combined with chemotherapy is the standard treatment in patients with metastatic colorectal cancer (mCRC). The present phase III study was…”
Get full text

Modified open posterior internal sphincterotomy with sliding skin graft for chronic anal fissure and anal stenosis: Low recurrence rate and no serious faecal incontinence postoperative complication by Iida, Y., Honda, K., Iida, R., Saitou, H., Munemoto, Y., Tanaka, A., Tanaka, H.

“…AIMLateral internal sphincterotomy (LIS) remains a standard for chronic anal fissure even though other surgical techniques have shown high efficacy. Faecal…”
Get full text

Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial) by Kanai, M., Kawaguchi, T., Kotaka, M., Shinozaki, K., Touyama, T., Manaka, D., Ishigure, K., Hasegawa, J., Munemoto, Y., Matsui, T., Takagane, A., Ishikawa, H., Matsumoto, S., Sakamoto, J., Saji, S., Yoshino, T., Ohtsu, A., Watanabe, T., Matsuda, F.

“…Peripheral sensory neuropathy (PSN) is a dose-limiting toxicity of oxaliplatin-based chemotherapy. Several genetic markers have been shown to predict…”
Get full text

SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results by Takahashi, M., Munemoto, Y., Nakamura, M., Kotaka, M., Kuroda, H., Kato, T., Minagawa, N., Noura, S., Fukunaga, M., Kuramochi, H., Touyama, T., Takahashi, T., Akagi, Y., Satake, H., Kurosawa, S., Miura, T., Mishima, H., Sakamoto, J., Oba, K., Nagata, N.

Get full text

Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration by Takeuchi, S., Yoshino, T., Yamanaka, T., Kotaka, M., Manaka, D., Eto, T., Hasegawa, J., Takagane, A., Nakamura, M., Kato, T., Munemoto, Y., Bando, H., Taniguchi, H., Gamoh, M., Shiozawa, M., Saji, S., Maehara, Y., Mizushima, T., Ohtsu, A., Mori, M.

Get full text

Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration by Yoshino, T., Yamanaka, T., Kotaka, M., Manaka, D., Eto, T., Hasegawa, J., Takagane, A., Nakamura, M., Kato, T., Munemoto, Y., Nakamura, F., Bando, H., Taniguchi, H., Gamoh, M., Shiozawa, M., Sakamoto, J., Saji, S., Mizushima, T., Ohtsu, A., Mori, M.

Get full text

6089 POSTER Goshajinkigan (TJ-107) for Oxaliplatin-induced Sensory Neurotoxicity in Colorectal Cancer Patients – a Prospective, Randomized, Double-blinded, Placebo-controlled, Phase II Trial (GONE) by Matsui, T, Kono, T, Hata, T, Fukunaga, M, Munemoto, Y, Nagata, N, Shimada, M, Morita, S, Sakamoto, J, Mishima, H

Get full text

323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial by Makiyama, A., Yamazaki, K., Shiozawa, M., Manaka, D., Kotaka, M., Sakamoto, Y., Shiomi, A., Munemoto, Y., Rikiyama, T., Fukunaga, M., Takashi, U., Shitara, K., Shinkai, H., Tanida, N., Oki, E., Misumi, T., Sunami, E., Ohtsu, A., Maehara, Y., Yoshino, T.

Get full text

300MO Impact of dihydropyrimidine dehydrogenase (DPD) genotype on fluoropyrimidine-related toxicity in Asian population by Kanai, M., Kawaguchi, T., Kotaka, M., Manaka, D., Hasegawa, J., Takagane, A., Munemoto, Y., Kato, T., Eto, T., Touyama, T., Matsui, T., Shinozaki, K., Mizushima, T., Matsumoto, S., Mori, M., Ohtsu, A., Saji, S., Yoshino, T., Matsuda, F.

Get full text

407P Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for high-risk stage II colon cancer: ACHIEVE-2 as part of the IDEA collaboration by Kotaka, M., Shiozawa, M., Manaka, D., Sakamoto, Y., Shiomi, A., Makiyama, A., Munemoto, Y., Rikiyama, T., Fukunaga, M., Ueki, T., Shitara, K., Shinkai, H., Tanida, N., Oki, E., Yamanaka, T., Sunami, E., Yamazaki, K., Ohtsu, A., Maehara, Y., Yoshino, T.

Get full text

401MO OS and long-term DFS with 3- vs. 6-month adjuvant oxaliplatin and fluoropyrimidine-based therapy for stage III colon cancer patients: A randomized phase III ACHIEVE trial by Yoshino, T., Kotaka, M., Manaka, D., Eto, T., Hasegawa, J., Takagane, A., Nakamura, M., Kato, T., Munemoto, Y., Nakamura, F., Bando, H., Taniguchi, H., Sakamoto, Y., Shiozawa, M., Nishi, M., Horiuchi, T., Mizushima, T., Yamanaka, T., Ohtsu, A., Mori, M.

Get full text

415P Prognostic effect of postoperative serum carcinoembryonic antigen (CEA) combined with T4 versus T3 tumors in patients with high-risk stage 2 colon cancer: ACHIEVE-2 phase III randomized clinical trial by Shiomi, A., Shiozawa, M., Manaka, D., Kotaka, M., Sakamoto, Y., Makiyama, A., Munemoto, Y., Rikiyama, T., Fukunaga, M., Ueki, T., Shitara, K., Shinkai, H., Tanida, N., Oki, E., Yamanaka, T., Sunami, E., Yamazaki, K., Ohtsu, A., Maehara, Y., Yoshino, T.

Get full text

525OACHIEVE-2 trial: A randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC) by Yoshino, T, Yamanaka, T, Shiozawa, M, Manaka, D, Kotaka, M, Gamoh, M, Shiomi, A, Makiyama, A, Munemoto, Y, Rikiyama, T, Fukunaga, M, Ueki, T, Shitara, K, Shinkai, H, Tanida, N, Yamazaki, K, Sunami, E, Ohtsu, A, Maehara, Y

“…Abstract Background The IDEA collaboration, a prospective pooled analysis of four concurrently conducted randomized phase III trials (SCOT, TOSCA, ACHIEVE-2,…”
Get full text

571PRandomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study by Nagasaka, T, Inada, R, Ojima, H, Noura, S, Tanioka, H, Munemoto, Y, Shimada, Y, Ishibashi, K, Shindo, Y, Kagawa, Y, Tomibayashi, A, Okamoto, K, Tsuji, A, Tsuji, Y, Yamaguchi, S, Sawaki, A, Mishima, H, Shimokawa, M, Okajima, M, Yamaguchi, Y

“…Abstract Background The C-cubed study investigates the optimal treatment strategy in patients with untreated metastatic colorectal cancer (mCRC). We tested the…”
Get full text

571P - Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study by Nagasaka, T., Inada, R., Ojima, H., Noura, S., Tanioka, H., Munemoto, Y., Shimada, Y., Ishibashi, K., Shindo, Y., Kagawa, Y., Tomibayashi, A., Okamoto, K., Tsuji, A., Tsuji, Y., Yamaguchi, S., Sawaki, A., Mishima, H., Shimokawa, M., Okajima, M., Yamaguchi, Y.

“…The C-cubed study investigates the optimal treatment strategy in patients with untreated metastatic colorectal cancer (mCRC). We tested the superiority of a…”
Get full text